Cargando…
Timing of paclitaxel treatment in pre‐operative or post‐operative does not affect survival in breast cancer patients
BACKGROUND: Two epirubicin and paclitaxel‐based neoadjuvant chemotherapy regimens were compared in breast cancer patients. METHODS: We enrolled 309 breast cancer patients who received two types of regimens: cyclophosphamide + epirubicin dose‐dense neoadjuvant chemotherapy followed by sequential post...
Autores principales: | Wang, Jiayu, Chen, Shanshan, Xu, Binghe, Yuan, Peng, Ma, Fei, Li, Qing, Zhang, Pin, Cai, Ruigang, Fan, Ying, Luo, Yang, Li, Qiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415454/ https://www.ncbi.nlm.nih.gov/pubmed/28402606 http://dx.doi.org/10.1111/1759-7714.12433 |
Ejemplares similares
-
Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial
por: Yuan, Peng, et al.
Publicado: (2023) -
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016) -
Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts
por: Wang, Jingjing, et al.
Publicado: (2017) -
Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023) -
Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)